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A simple, accurate, and precise method to determine adenovirus particle concentration using 260-nm absorbance was
developed as an enhancement to the method of Maizel et al. (1968, Virology 36, 115–125). This modified method ensures
complete disruption of virus particles and viral DNA prior to absorbance measurements, therefore eliminating absorbance
measurement errors due to hyperchromic shift and thus providing an extinction coefficient at 260 nm that is directly related
to protein concentration as measured by the method of Lowry et al. (1951, J. Biol. Chem. 193, 265–275). Application of this
modified method will reduce interlaboratory variability in determining adenovirus particle concentrations, as current prac-
tices reflected in the literature utilize varying sample preparation procedures and calculation methods which cause
underestimation of adenovirus concentration by almost twofold. The sample pretreatment conditions used in this modified
method entail incubation in 1% sodium dodecyl sulfate at 100°C for 4 min and result in an adenovirus 260-nm absorptivityit in a
e; viralINTRODUCTION
The introduction of adenovirus as a vector for in vivo
delivery of transfected genes used in therapeutic treat-
ments, as well as in vaccines, has resulted in a realm of
highly focused research and development that will ulti-
mately be applied to many different disease targets.
Clinical studies used to estimate dosage levels of trans-
fected adenovirus particles for appropriate efficacy are
highly dependent upon techniques that can provide ac-
curate and reproducible methods to assess viral particle
concentration. Several methods for determining adeno-
virus particle concentration using spectroscopic meth-
ods with various types of sample pretreatments have
been published in the literature (Lawrence and Ginsberg,
1967; Maizel et al., 1968; Liebermann and Mentel, 1994;
Huyghe et al., 1995; Mittereder et al., 1996; Shabram et
al., 1997). No one method, however, has been applied in
a consistent enough manner to provide a “universal”
approach for defining adenovirus concentration. Further-
more, many of these methods produce conflicting re-
sults. In fact, Mittereder et al. (1996) state in a work
intended to evaluate concentration and bioactivity of
adenovirus that the accuracy of the absorptivity of ade-
novirus preparations at 260 nm is an area that needs to
be further investigated.
Establishment of a rugged ultraviolet (UV) absorbance
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284method to assess adenovirus particle concentration has
several requirements: (1) accurate evaluation of viral
mass, such as by direct quantitation of virus protein
content; (2) evidence of compositional consistency be-
tween preparations to be evaluated with regard to those
elements that significantly impact the measurement; and
(3) assurance that the analytical method will result in
equal and consistent evaluation of all samples. Maizel et
al. (1968) established a correlation between protein con-
tent of adenovirus preparations and absorbance at 260
nm and reported an absorptivity for purified adenovirus
preparations of 1.1  1012 viral particles per absorbance
unit (AU). This method and absorptivity value have been
cited extensively in the literature as the basis for quan-
titating adenovirus particle concentration. While the sim-
plicity of this spectroscopic method is attractive, appli-
cation in our laboratory resulted in poor accuracy when
compared to direct evaluation of protein concentration
and higher intra- and interassay variability than would be
expected from a spectroscopic method. Further investi-
gations revealed that the prescribed sample treatment
method used to prepare adenovirus preparations for
spectroscopic evaluation was inadequate to ensure con-
sistent disruption of the virus particles and complete
unfolding of the viral DNA. This led, in turn, to variable
contributions to the 260-nm absorbance measurements
(1) from the variable degrees of hyperchromism associ-
ated with variable amounts of random coil DNA relative
to helical DNA and (2) to a lesser degree from scatteredof 1.8  1012 viral particles per milliliter per absorbance un
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light caused by remnant virus particles. The magnitude
of the hyperchromic effect, which is exhibited as an
increase in absorbance at 260 nm, is related to the
degree of DNA disruption (Tinoco, 1959; Rhodes, 1961;
Painter and Koenig, 1976). Moreover, since Maizel’s fac-
tor is apparently derived from adenovirus that is not
completely disrupted prior to absorbance measurement,
and the incubation period is very loosely defined (i.e.,
overnight), there is likely to be difficulty in achieving
consistent DNA disruption between experiments and be-
tween laboratories using the same methods. Thus, the
factor that Maizel empirically derived may not be appli-
cable to other experiments in which the DNA is disrupted
to a different degree or, as preferable, to a degree of
complete disruption.
This work describes the experimental results used to
provide a consistent and reproducible method for deter-
mining adenovirus particle concentration. These results
are based on extensive spectroscopic analyses, includ-
ing a rugged sample preparation method and rigorous
determinations of protein concentration. Subsequent ap-
plication of this methodology to several purified adeno-
virus preparations produced spectroscopic determina-
tions of virus particle concentration that correlate ex-
tremely well with independent protein concentration
measurements, confirming an assay precision of 10%
(1 relative standard deviation, RSD). Overall, the method
reported here provides a simple, robust, and rugged
approach for defining adenovirus particle concentration
that produces a more accurate and precise result than
previously established methods.
RESULTS AND DISCUSSION
Protein concentration assay
Protein concentration analysis was performed seven
times over a period of 6 months using a single reference
preparation (lot A) of purified adenovirus. The results are
summarized in Table 1. Overall, the results are very
consistent, providing a viral particle concentration for
this lot of 4.9  1011 vp/ml (based on protein concentra-
tion) with an RSD of 2.8%.
UV absorbance assay
Typically, the blank samples showed absolute absor-
bance values of ca. 0.1 AU. However, in some cases
leaching of UV-absorbing material from polypropylene
tubes resulted in absorbance values for the matrix blank
of up to 0.4 AU, depending upon tube manufacturer.
Increased absorbance due to leaching was relatively
consistent for analyses performed with a single lot of
tubes at a specific SDS concentration and within a given
run. Subtraction of the blank absorbance value from the
test sample absorbance value was sufficient to minimize
the impact of the leaching on the evaluation of the test
samples. For these reasons, the overall accuracy of the
absorbance difference seemed to be unaffected by the
leaching problem; however, retrospective analysis of the
data suggested that the precision of the assay result was
better at lower blank absorbance values. These results
suggest that it would in general be better to use glass
tubes for sample preparation in this assay in order to
avoid concerns about leaching of UV-absorbing material
from polypropylene tubes.
The 11 purified adenovirus preparations used in this
study exhibited A 260/A 280 absorbance ratios ranging from
1.23 to 1.33 (see Table 2) with an overall average of
1.28  0.02, reflecting a reasonably consistent nucleic
acid to protein ratio in these preparations. Although the
adenovirus A 260/A 280 absorbance ratios are typical and
fairly precise, as would be expected from a purified
preparation, it should be noted that the types of spectro-
scopic analyses used in this study are fairly insensitive
to residual host cell protein impurities as both the
260-nm absorbance and the A 260/A 280 ratios are domi-
nated by the nucleic acid signal. Furthermore, residual
host cell nucleic acids would have to be on the order of
greater than a few percent of total nucleic acids to
significantly influence these readings and this would be
orders of magnitude greater than would be likely in a
purified adenovirus preparation. As such, use of the
adenovirus 260-nm absorptivity generated here is rela-
tively insensitive to absorbance contributions from resid-
ual levels of host cell contaminants in purified adenovi-
rus preparations.
The absorbance difference data at 260 nm between
test sample and blank were generated for the control
TABLE 1
Summary of Protein Concentration Assay Results and Calculated
Viral Particle Concentration Data from Replicate Analysis of a Single
Control Preparation (Lot A) of Purified Adenovirus
Test run
Protein
concentration
(g/ml)
Viral particle
concentrationa
(1011 vp/ml)
1 124 4.8
2 125 4.9
3 125 4.9
4 127 5.0
5 119 4.7
6 128 5.0
7 130 5.1
Average 125.6 4.9
SD 3.5 0.14
% RSD 2.8% 2.8%
a Viral particle concentrations (vp/ml) were calculated from the pro-
tein concentration measurements as follows: Molecular weight (MW)
viral DNA  2.3  107 g/mol virus (Green et al., 1967), and DNA is 13%
of virion dry weight (Green and Pin˜a, 1964). Therefore, the MW of the
viral particle 1.76 108 g/mol virus and MW viral protein 1.54 108
g/mol. Protein mass per viral particle  MW viral protein/Avogadro’s
Number  2.56  1010 g protein/viral particle. Viral particle concen-
tration  Protein concentration/Protein mass per viral particle.
285ADENOVIRUS ABSORPTIVITY AT 260 nm
preparation (lot A) of purified adenovirus in order to
establish an absorptivity value at 260 nm (260). Absor-
bance differences for this single preparation were ac-
quired in 26 separate analyses on 9 different days
throughout a 7-month period to provide insights on assay
variability and ruggedness. These absorbance measure-
ments were obtained using a twofold dilution of the
purified adenovirus sample with SDS pretreatment as
described above.
Figure 1 shows the nine daily averages and standard
deviations for the 260-nm absorbance difference data,
A 260 (i.e., A 260-test minus A 260-blank), along with the number
of analyses per day. The results suggest that multiple
preparations should be tested to obtain an accurate
result, as occasional individual results were shown to
differ by up to 15% from the global average, whereas
typically the average of any three proximate analyses
differed by about 5%. The overall similarity of the within-
day and between-day variability suggests that the occa-
sionally high variability observed in two of the replicate
analyses was likely associated with pipetting variability
and/or differential evaporation of the small volume sam-
ples during the heating/cooling cycle of the sample treat-
ment. The latter situation can be eliminated by ensuring
that the sample tubes are capped tightly during the
pretreatment incubation and mixed thoroughly by inver-
sion and vortex after cooling to room temperature,
postincubation. In any event, by performing triplicate
analyses of any given sample on the same day or on
different days, the average result would be expected to
have an RSD on the order of 4%.
The overall assessment of the UV absorbance data for
lot A provides an estimate of the A 260 value of 0.135
absorbance units with an RSD of 9.1%. Using this aver-
age absorbance value for lot A, the average viral particle
concentration for lot A provided in Table 1, and a dilution
factor of 2, the 260-nm absorptivity (260) of this purified
adenovirus preparation can be calculated to be 1.8 
1012 vp/ml-AU-cm. Given that this absorptivity value re-
flects the variability of both the protein concentration
assay and the UV absorbance assay, propagation of
error results in a final precision of 9.5% RSD for the
estimate of adenovirus 260. This absorptivity value,
based on seven repeats of the protein concentration
analysis and 26 independent determinations of the A 260
value, provides a rigorous determination of the 260 of a
purified adenovirus preparation. Thus, one can deter-
mine the viral particle concentration of similar adenovi-
rus preparations using this 260 value along with the
simple, rugged analytical methodology described in this
report.
Ten additional purified adenovirus preparations were
analyzed for UV absorbance and protein concentration
using the same methods as described for the analyses of
lot A. Evaluation of different lots permitted both applica-
tion of the newly derived 260 value for calculation of viral
particle concentrations and demonstration that the rela-
tionship between viral particle concentration based on
UV absorbance analyses versus viral particle concentra-
tion based on protein concentration analyses did not
vary significantly from lot to lot. As an additional mea-
sure, the A 260/A 280 absorbance ratio was calculated for
each virus preparation to assess the consistency of the
relative purity of these preparations. These data are
presented in Table 2.
Viral particle concentrations derived solely from pro-
tein concentration analyses do not incorporate the ab-
sorptivity factor and can thus be considered as “orthog-
onal” to the spectroscopic measurement. These data are
presented in Fig. 2 (data symbol }) as comparisons of
FIG. 1. Absorbance difference data (test sample minus blank) at 260
nm derived from 26 individual analyses of adenovirus control lot A
displayed as within-day averages for various replicate analyses per
day. Analyses were conducted on 9 different days over a 7-month
period. Within-day standard deviations are shown by the error bars;
replicates analyzed per day are also listed.
TABLE 2
Viral Particle Concentration Results for 11 Purified Adenovirus
Preparations as Determined by Protein Concentration Analysis (Col-
umn 3) and UV Absorbance Using the Modified Method and 260 Value
of 1.8  1012 Virus Particles/ml-AU-cm (Column 4)
Adenovirus lot
Ratio
A 260/A 280
Virus particle concentration
(1011 vp/ml)
Protein assay Modified UV assay
A 1.33 4.9 4.9
B 1.27 78.1 81.7
C 1.28 2.7 3.0
D 1.29 3.2 3.5
E 1.23 4.5 5.3
F 1.28 4.5 5.0
G 1.29 6.7 7.4
H 1.28 6.5 7.2
I 1.27 6.7 7.8
J 1.29 4.6 4.3
K 1.26 14.3 15.2
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the viral particle concentrations derived by UV absor-
bance relative to that derived from direct protein concen-
tration analysis. The correlation between the two sets of
results is extremely good, providing an r 2 value in excess
of 0.999. This result confirms a very consistent nucleic
acid to protein ratio in these virus preparations. Addition-
ally, the fact that the slope of the regression line for the
modified UV assay is very close to 1.0 supports the
notion that the 260 value derived here, 1.8  10
12 vp/ml-
AU-cm, will permit determination of viral particle concen-
trations from UV absorbance data that are in fairly pre-
cise agreement with those derived from more laborious
protein concentration estimates. Moreover, the results
from both of these methods correlate well with viral
particle concentrations derived from another orthogonal
method, quantitative polymerase chain reaction analy-
ses, which quantitates the viral DNA content of purified
adenovirus preparations (Dr. Fubao Wang and Dr. John
Lewis, personal communication).
Further, the advantage of the modified UV absorbance
method with newly derived adenovirus 260-nm absorp-
tivity (260) described here versus use of the absorptivity
factor derived by Maizel becomes readily apparent when
a similar comparative plot of UV-absorbance-derived vi-
ral particle concentration (based on Maizel’s factor) ver-
sus the viral particle concentration derived solely from
protein concentration is examined in Fig. 2 (data symbol
). As expected, the results using the Maizel factor differ
significantly, with viral particle concentrations that are
not only 40% lower than those derived using our 260
value, but that also exhibit a slope for the viral particle
concentration correlation (i.e., UV-derived versus protein-
derived) of far less than 1.0. This latter result supports the
notion that the methodology described herein results in
a more accurate assessment of viral particle concentra-
tion.
Overall, the methodology defined in this study allowed
determination of a 260-nm absorbance value for purified
adenovirus preparations that could be used along with
the newly derived 260-nm adenovirus absorptivity to di-
rectly determine viral particle concentration by means of
simple, rugged analyses that produce results consistent
with those derived independently from protein concen-
tration analyses by classical methods (i.e., the method of
Lowry). Application of this methodology and associated
260-nm absorptivity value as a general method for char-
acterizing purified adenovirus preparations may provide
the general utility seen over the past decade with the
Maizel method, but with more accurate results and much
improved interlaboratory ruggedness. These attributes
will be of general use to the adenovirus research com-
munity.
MATERIALS AND METHODS
Purified serotype 5 adenovirus preparations were pro-
vided by Merck Research Laboratories, Fermentation
and Cell Culture Department and Vaccine Bioprocess
Engineering Department. Briefly, adenovirus cultured in a
host cell line was harvested, followed by host cell lysis
under freeze/thaw conditions with enzyme treatment.
Centrifugation and filtration steps preceded virus purifi-
cation by anion-exchange chromatography. Chromato-
graphic eluant containing the purified adenovirus was
collected and dia-filtered into the final buffer system
followed by sterile filtration as the final step. Purified
adenovirus samples were stored at less than 65°C
prior to any analyses. The final matrix for the adenovirus
preparation was a phosphate-buffered saline (PBS)-
based system with low concentrations of excipients
added for stability. Only purified adenovirus preparations
with an A 260/A 280 absorbance ratio of 1.2 to 1.3 were
included in this study.
Protein concentrations of adenovirus samples were
determined by the method of Lowry et al. (1951), cali-
brated with bovine serum albumin (BSA) standards from
either NIST or Pierce Chemical Co. Protein content per
virion was calculated to be 2.56  1010 g protein/vp
based on a previously established viral DNA molecular
weight of 2.3  107 g DNA per mole of virus with viral
DNA content comprising 13% of virion dry weight for
adenovirus serotype 2 (Green and Pin˜a, 1963, 1964;
Green et al., 1967). This DNA molecular weight is in
excellent agreement with that calculated (2.32  107 g
DNA per mole of viral particle) from the single-strand
FIG. 2. Correlation plot of viral particle concentration data for 10
different adenovirus preparations as determined from the UV absor-
bance analysis versus the direct protein analysis. Data for UV-absor-
bance-derived viral particle concentration is shown for application of
both the 260 value (1.8  10
12 vp/ml-AU-cm) derived herein (}) and the
260 value derived by Maizel et al. (1968) ().
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sequence of the adenovirus serotype 2 or serotype 5
genomes displayed in the GenBank database (i.e.,
35,937 bp with a base content of 8342 A, 10,045 C, 9793
G, and 7757 T for serotype 2 and 35,935 bp with a base
content of 8367 A, 10,073 C, 9761 G, and 7734 T for
serotype 5). Further, it is reported that the adenovirus
serotype 5 gene sequence is greater than 95% homolo-
gous with the adenovirus serotype 2 gene sequence
(Green et al., 1979; Chroboczek et al., 1992). Viral particle
concentrations were calculated from protein concentra-
tions by dividing experimentally derived protein concen-
trations by the constant of 2.56  1010 g protein per
virion. All protein assays included BSA calibration stan-
dards over the range of 2.8 to 20 g BSA and a reference
preparation of purified adenovirus.
Absorbance measurements of adenovirus samples at
260 nm were acquired using a Beckman diode array
spectrophotometer set to zero absorbance with a water
background. Submicro-quartz cuvettes (Starna Cells)
with a sample volume of 40 l and a pathlength of 1 cm
were used for absorbance measurements. The same
cuvette was used to measure samples and blanks. Test
samples were brought to 1.0% (w/v) sodium dodecyl
sulfate, tightly capped, and incubated in a heating block
at 100°C 1°C for 4 min. After incubation, samples were
cooled to room temperature and thoroughly mixed by a
minimum of five inversion and vortex cycles prior to the
absorbance measurements. Blank samples containing
the PBS-based test sample matrix without adenovirus
were treated in the same manner to account for excipient
and reagent contributions to the absorbance at 260 nm.
In order to maintain an acceptable level of accuracy
and precision in the assay, only absorbance differences
between test samples and matrix blanks of greater than
0.05 AU were used. Also, to ensure that absorbance
measurements were linear within the limits of the instru-
mentation and Beer’s Law, only absorbance measure-
ments of less than or equal to 1 AU were considered
acceptable. If an absorbance value of greater than 1 AU
was observed for the test samples, the entire measure-
ment, including sample pretreatment, was repeated us-
ing an appropriate dilution of the original test sample. It
is recommended that absorbance contributions due to
excipients in the matrix blank, diluted equivalently as the
test sample, should not exceed an absolute absorbance
of 0.5 AU. This limit permits an additional absorbance
contribution of 0.5 AU from the adenovirus in an equiva-
lently diluted test sample before reaching the recom-
mended absolute absorbance limit for a test sample of
1.0 AU.
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